LifeSci Capital Upgrades Liquidia (LQDA) to Outperform Following
LifeSci Capital upgraded Liquidia (LQDA) to Outperform with a $59 price target, citing a recent settlement with United Therapeutics that resolved all outstanding lawsuits. LQDA is trading at $26.81, which is 90.6% below its GF Value™ of $285.95, indicating potential undervaluation. The company's GF Score™ is 69, reflecting strong growth but weak profitability and valuation. Insiders have sold $230.5 million in shares over the past year, while two gurus hold positions in LQDA.
How this was made
The 30-second read
Why it matters
The settlement removes a cloud over the stock, prompting an analyst upgrade and a new $59 price target, which could drive buying interest.
Market read
Upgrade and settlement are fresh, material news for LQDA, offering a potential trade catalyst.
What to watch
Potential off‑label use of YUTREPIA may limit revenue upside.
Background
Liquidia (LQDA) is a biopharma developing inhaled therapies for pulmonary hypertension. The company settled six lawsuits with United Therapeutics, clearing a major risk.
Ticker impact
LifeSci Capital upgraded Liquidia to Outperform and set a $59 price target after the settlement with United Therapeutics removed legal overhang.
likely upward pressure as investors price in the settlement and higher target.
The settlement eliminates litigation risk and the new target suggests a sizable upside from current levels.
Market effects
May lift sentiment for other small‑cap biotech firms with pending litigation.
Limited to US biotech sector.
Low; primarily a micro‑cap US stock event.
Counterpoint
Heavy insider selling could signal lingering concerns despite the upgrade.
Key entities
- analystLifeSci Capital
Research firm that issued the Outperform rating and $59 target.
- partnerUnited Therapeutics
Settled all pending litigation with Liquidia.
